Next Quarterly Earnings
Date confirmed from the company's own financial calendar.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Formycon AG is a biopharmaceutical company headquartered in Germany, specializing in the development and manufacturing of high-quality biosimilars. The company focuses on complex biopharmaceuticals within the therapeutic areas of ophthalmology, immunology, and oncology, aiming to provide patients with access to affordable and effective medications. Formycon is driving the development of promising biosimilar candidates.
Date confirmed from the company's own financial calendar.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Formycon is scheduled to report its next quarterly earnings on 11/12/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Formycon last reported quarterly earnings on 8/12/2026 (Q2 2026). Earnings per share (EPS) came in at -0.83 EUR.
Across its last 3 earnings reports, Formycon stock moved by ±2.7% on average the following day. The largest reaction was -4% on 04/22/2026; 1 of 3 reactions were positive.
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 3 report dates (close to close).
Past price reactions are not a reliable indicator of future performance.